Part 4

From my experience as a mental health clinician, it's vital to emphasize that prolactin elevation during risperidone treatment is a predictable pharmacologic side effect rather than a sign of therapeutic success. Patients often worry when they learn their prolactin levels are high, but clinical response must be judged by symptom improvement rather than lab values alone. In practice, I have found that monitoring should focus on symptoms such as galactorrhea, menstrual changes, sexual dysfunction, and gynecomastia rather than routine prolactin lab testing in asymptomatic patients. This symptom-driven approach helps avoid unnecessary anxiety and interventions. When significant symptoms arise, evaluating prolactin levels is crucial and guides management decisions. Options include lowering the risperidone dose when feasible, switching to a prolactin-sparing antipsychotic, or adding adjunctive treatments such as aripiprazole, which has partial dopamine agonist properties that may counteract hyperprolactinemia. It’s also important to consider individual patient contexts—some patients tolerate mild prolactin elevation without distress or functional impairment, while others experience significant quality of life impact. A collaborative discussion with patients about these risks and benefits fosters adherence and trust. Overall, balancing risperidone’s therapeutic efficacy with minimizing endocrine side effects ensures optimal psychiatric care. This nuanced understanding aligns with guidelines from the Endocrine Society and psychiatric organizations recommending symptom-focused prolactin monitoring rather than routine lab checks in absence of clinical concerns.